A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...

In parallel, MerryLife is exploring the potential relevance of TML-6 in Parkinson's disease, where similar pathological mechanisms contribute to disease progression. The company will present ...

Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with ...

European Commission announces new cybersecurity measures Includes phase-out of equipment from 'high-risk' suppliers Proposed restrictions seen targeting Chinese tech BRUSSELS, Jan 20 (Reuters) - The ...

You may have missed it due to the firehose of international news over the last week. But in between the CIA director traveling to Venezuela to meet deposed dictator Nicolás Maduro’s replacement and ...

The US announced the start of the next phase of the Gaza ceasefire plan on Wednesday as a new committee was formed to run the battered enclave. US Special Envoy Steve Witkoff said the second phase of ...

A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...

Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella’s QTORIN rapamycin platform demonstrates high ...

Belgian marine contractor Jan De Nul has launched its newest cable laying vessel (CLV), the Fleeming Jenkin, at the CMHI Haimen shipyard in China, which has now entered the final phase of construction ...

TMC the metals company appears furthest advanced in deep-sea nodule mining, as it's now advancing under a U.S. regulatory framework. The recent PFS study for NORI-D and IA study for further ...